TNFRSF10C Antibody
Description
Clinical and Oncological Relevance
TNFRSF10C aberrations correlate with aggressive cancer phenotypes:
Metastatic Colorectal Cancer (CRC)
-
Copy number variation (CNV): Homozygous deletions in TNFRSF10C associate with distant metastasis (P<0.001), nodal involvement (P=0.005), and positive resection margins (P<0.001) .
-
Therapeutic implications: CNV may identify patients requiring intensified systemic therapy .
Non-Small Cell Lung Cancer (NSCLC)
-
Hypermethylation: Promoter methylation silences TNFRSF10C expression, particularly in non-smokers and males (P<0.05) .
-
Reversal by demethylation: 5′-aza-deoxycytidine treatment restores mRNA expression in A549 and H1299 cell lines .
Mechanisms of Action in Research Settings
TNFRSF10C antibodies enable precise pathway interrogation:
-
Neutralization assays: MAB630 inhibits TRAIL-R3-mediated cytoprotection at ND50 values of 0.02–0.08 µg/mL .
-
Epigenetic regulation studies: Antibodies detect expression changes following demethylating therapies .
Applications in Experimental Models
Future Research Directions
-
Biomarker validation: Correlate TNFRSF10C CNV/methylation status with clinical outcomes in prospective trials.
-
Therapeutic targeting: Develop antibody-drug conjugates to exploit TRAIL-R3 overexpression in resistant tumors.
-
Combination therapies: Test demethylating agents with TRAIL agonists to reverse apoptotic resistance .
Product Specs
Target Background
TNFRSF10C plays a significant role in various biological processes and has been implicated in several diseases. Here are some notable findings from research studies:
- High levels of TNFRSF10C and CCR-2 expression in tumor epithelial cells identified patients with early breast cancer with poor outcomes. PMID: 28420351
- Serum TNFRSF10C levels were significantly lower in patients with Age-Related Macular Degeneration (AMD). PMID: 24534820
- Upregulation of TNFRSF10C mediates resistance to temozolomide, a chemotherapy drug. PMID: 25808868
- Hypermethylation of the TNFRSF10C and GATA4 promoters is a tumor-specific event in glioblastoma. However, promoter methylation cannot be considered a prognostic marker of glioblastoma survival. PMID: 23320456
- Primary epithelial ovarian cancer (EOC) is associated with lower TNFRSF10C expression. PMID: 22555108
- Data indicate that approximately 20% of acute myeloid leukemia (AML) patients exhibit high expression of TNFRSF10C, which was strongly correlated with a shortened overall survival. PMID: 21281967
- Decoy receptors TNFRSF10C and DcR2 on CD8+ T cells, but not on CD4-positive T cells, are positively correlated with patients' Disease Activity Score (DAS) scores. PMID: 20799941
- Findings suggest that TNFRSF10C expression occurs in a subset of endometrial carcinomas and may contribute to resistance to TRAIL-induced apoptosis. PMID: 19936781
- Research has analyzed the transcription initiation sites and promoter structure of the TNFRSF10C gene. PMID: 12417331
- A p53 consensus element located within the first intron of the TNFRSF10C gene has been cloned and characterized. PMID: 14623878
- Studies demonstrate that the TNFRSF10C and DcR2 genes are frequently methylated in various tumor types, and aberrant methylation was the cause for silencing of TNFRSF10C and DcR2 expression. PMID: 14999791
- TNFRSF10C lacks a death domain and is anchored to the membrane via a glycophosphatidyl inositol tail. PMID: 15538968
- Resistance to TRAIL-induced apoptosis in acute myeloid leukemia cells is associated with the expression of TNFRSF10C. PMID: 15921376
- Tryptophol induces apoptosis through DR5, and the resistance of peripheral blood leukocytes (PBL) to tryptophol-induced apoptosis might be due to competition from TNFRSF10C. PMID: 17690453
- p53 negatively regulates oxaliplatin-mediated TRAIL-induced apoptotic activity through TNFRSF10C upregulation. PMID: 18345033
- TNFRSF10C levels were significantly higher in lung parenchyma in subjects with emphysema. PMID: 18511705
- Liver metastases with low TNFRSF10C mRNA expression were more likely to present with extrahepatic metastases. PMID: 18590575
- Inactivation of TNFRSF10C by chromosomal deletion and promoter methylation may play a significant role in prostate cancer development. PMID: 19035483
- Low TNFRSF10C expression is associated with non-small cell lung cancer. PMID: 19661294
